Australia markets open in 9 hours 55 minutes

Protagenic Therapeutics, Inc. (MBP.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
0.8750+0.0500 (+6.06%)
As of 10:51AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 4.07M
Enterprise value -456.19k
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.85
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.10

Trading information

Stock price history

Beta (5Y monthly) 0.32
52-week change 3-52.59%
S&P500 52-week change 324.96%
52-week high 31.9400
52-week low 30.6380
50-day moving average 31.1204
200-day moving average 30.9903

Share statistics

Avg vol (3-month) 352
Avg vol (10-day) 3N/A
Shares outstanding 54.45M
Implied shares outstanding 64.93M
Float 83.22M
% held by insiders 121.83%
% held by institutions 117.53%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 323 Mar 2023

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-67.43%
Return on equity (ttm)-140.56%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -5.49M
Net income avi to common (ttm)-6.01M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.42M
Total cash per share (mrq)0.55
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)5.53
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-4.99M
Levered free cash flow (ttm)-3.35M